Incretin Atlas › Trials › STEP 9
STEP 9
Semaglutide · Knee osteoarthritis + obesity
Design
- Molecule(s)
- Semaglutide
- Population
- Knee osteoarthritis + obesity
- Official title
- Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2021-10 → 2023-07
- Participants
- 407
- Duration
- 68 weeks
- Registry
- NCT05064735
Outcomes in the indication
STEP 9 Semaglutide · Knee osteoarthritis + obesity · 68 weeks · n = 407 seed
WOMAC pain −41.7 vs −27.5 points; weight −13.7 % vs −3.2 %
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: STEP 9. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-9/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.